U.S. Markets close in 3 hrs 29 mins
  • S&P 500

    -38.27 (-0.87%)
  • Dow 30

    -195.02 (-0.55%)
  • Nasdaq

    -267.22 (-1.80%)
  • Russell 2000

    -37.83 (-1.71%)
  • Crude Oil

    -0.52 (-0.72%)
  • Gold

    -0.50 (-0.03%)
  • Silver

    -0.75 (-2.97%)

    +0.0031 (+0.2604%)
  • 10-Yr Bond

    -0.0400 (-3.13%)
  • Vix

    +2.80 (+15.93%)

    +0.0056 (+0.4039%)

    -0.7650 (-0.6931%)

    -1,443.18 (-3.68%)
  • CMC Crypto 200

    +18.26 (+2.08%)
  • FTSE 100

    -29.35 (-0.42%)
  • Nikkei 225

    +136.93 (+0.49%)

OncBioMune Completes Enrollment in Phase 1 Trial of ProscaVax for Prostate Cancer

BATON ROUGE, LA--(Marketwired - May 03, 2017) - OncBioMune Pharmaceuticals, Inc. (OBMP) ("OncBioMune" or the "Company"), a clinical stage biopharmaceutical company engaged in the development of targeted cancer therapies and a proprietary vaccine technology, is pleased to announce that the 20 patient enrollment has been completed in the Company's Phase 1 clinical trial of ProscaVax as a novel vaccine treatment for prostate cancer. In the study, ProscaVax is being evaluated for safety, tolerability and efficacy in prostate specific antigen (PSA) progressing prostate cancer in hormone-naïve and hormone-independent patients. ProscaVax is an immunotherapeutic cancer vaccine consisting of a combination of the tumor-associated antigen PSA with the biological adjuvants interleukin-2 (IL-2) and granulocyte-macrophage colony-stimulating factor (GM-CSF).

The trial is being hosted at the University of California San Diego Moores Cancer Center and the Veterans Hospital in La Jolla, California under an IND from the U.S. Food and Drug Administration with funding from the U.S. Navy Cancer Vaccine Program. 20 patients have now been enrolled in the study, meeting protocol enrollment for the first stage of the study. The original study design included a second stage, which OncBioMune has previously disclosed that it will forego due to favorable interim safety results from the first stage to initiate two Phase 2 clinical trials evaluating ProscaVax in both late-stage prostate cancer and also in early-stage prostate cancer patients.

"We are very pleased to have reached this milestone to complete the first clinical trial of ProscaVax," commented Dr. Jonathan Head, Chief Executive Officer at OncBioMune. "The interim data to date has been extremely compelling, demonstrating the strong safety and tolerability profile of ProscaVax, as well as indications of efficacy with respect to slowing tumor progression and supporting an immune response to disease. Based upon the data and years of previous research, we remain optimistic that ProscaVax has a future as a meaningful therapeutic for the millions of people affected by prostate cancer."

Sign up for OncBioMune email alerts at: http://oncbiomune.com/email-alerts/.

About OncBioMune Pharmaceuticals, Inc.

OncBioMune Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a proprietary Vaccine Technology that is designed to stimulate the immune system to attack its own cancer while not hurting the patient. Our lead product, ProscaVax™ is scheduled to commence a Phase 2 clinical study in 2016. OncBioMune also has a portfolio of targeted therapies, some of which are biosimilars to blockbuster drugs. OncBioMune is headquartered in Baton Rouge, LA.

This press release does not constitute an offer to sell or a solicitation of an offer to buy the securities in this offering, nor there be any sale of these securities in any jurisdiction in which such offer solicitation or sale are unlawful prior to registration or qualification under securities laws of any such jurisdiction.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that could cause OncBioMune Pharmaceuticals' actual results and experience to differ materially from anticipated results and expectations expressed in these forward looking statements. OncBioMune Pharmaceuticals has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Among other factors that could cause actual results to differ materially from those expressed in forward-looking statements are OncBioMune Pharmaceuticals' need for, and the availability of, substantial capital in the future to fund its operations and research and development; the fact that OncBioMune Pharmaceutical's vaccines and therapeutics may not successfully complete pre-clinical or clinical testing, or be granted regulatory approval to be sold and marketed in the United States or elsewhere. A more complete description of these risk factors is included in OncBioMune Pharmaceutical's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. OncBioMune Pharmaceuticals undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.